Patent ID: 8367336
Filing Date: 2013-02-05
Classification: C12Q

Abstract:
1. A method for predicting overall survival or disease-free survival following adjuvant therapeutic treatment of a human subject having primary breast cancer, comprising: obtaining, prior to or during adjuvant therapeutic treatment of a human subject having a primary breast cancer, a biological sample comprising breast cancer cell genomic DNA from the subject, wherein the adjuvant therapeutic treatment comprises treatment with tamoxifen or estrogen receptor antagonist; treating the genomic DNA, or a portion thereof, with one or more reagents suitable to distinguish between cytosine and 5-methylcytosine bases; determining, based on the treating, a methylation state of at least one CpG dinucleotide sequence of nucleotides 2905-2990 of SEQ ID NO:9; and determining, based on the determined CpG methylation state, that the human subject has an increased likelihood of overall survival or disease-free survival following adjuvant therapeutic treatment if said CYP1B1 sequence is methylated, and that the human subject has a decreased likelihood of overall survival or disease-free survival following adjuvant therapeutic treatment if said CYP1B1 sequence is not methylated.